At what enterprise value was H2 PHARMA acquired in 2020?

You can find the full valuation details of H2 PHARMA on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of H2 PHARMA when it was acquired by ARDIAN?

The exact EV/EBITDA multiple for H2 PHARMA is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was H2 PHARMA acquired by ARDIAN?

H2 PHARMA was acquired by ARDIAN in 2020.

What was the revenue of H2 PHARMA at the time of the deal?

The revenue of H2 PHARMA at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the H2 PHARMA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the H2 PHARMA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/ardian-prend-une-participation-dans-h2-pharma-acteur-de-reference-dans-la

← DATABASE

Home Database Healthcare & PharmaH2 PHARMA

10/2020

H2 PHARMA acquired by ARDIAN

FRANCE Life Sciences / Pharma & Biotech / CDMO REV 25M - 50M EUR

Context

Ardian Growth acquired a minority stake in H2 Pharma in its inaugural healthcare investment. The partnership was established to support the company's ambitious industrial scaling, with a production target of 100 million units per year. The strategic roadmap focuses on internationalizing the group's footprint within the European market and diversifying its service offering to include regulatory affairs and analytical control. Ardian provides strategic support to leverage H2 Pharma's automated manufacturing processes and R&D capabilities, aiming to strengthen its position as a preferred CDMO partner for international pharmaceutical laboratories.

H2 PHARMA, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2009, H2 Pharma is a leading French specialist in the design and production of non-sterile liquid generic and OTC medicines (mouthwashes, syrups, oral solutions). A key partner for major pharmaceutical laboratories, the company controls the entire value chain, from R&D and Marketing Authorization (AMM) filings to automated production and regulatory affairs.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
01/2021	SAGARD	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
11/2020	NOVALPINA CAPITAL	LABORATOIRE X.O	FRANCE	Generics / Labs
10/2020	SULZER	HASELMEIER	SWITZERLAND	Medical Consumables
09/2020	PERMIRA	NEURAXPHARM	GERMANY	Generics / Labs
09/2020	EQT PARTNERS	SCHÜLKE	GERMANY	Medical Consumables
09/2020	PATRICIA INDUSTRIES	ADVANCED INSTRUMENTS	UNITED STATES	Diagnostic Equipment
06/2020	AVISTA CAPITAL PARTNERS	VISION HEALTHCARE	BELGIUM	Nutrition & Dietary Supplements
04/2020	ROYAL DSM	GLYCOM	DENMARK	Nutrition & Dietary Supplements
04/2020	AMERICAN SECURITIES	PARAGON MEDICAL	UNITED STATES	Medical Devices
04/2020	WARBURG PINCUS	POLYPLUS	FRANCE	R&D Biotech

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of H2 PHARMA by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: ardian